Teh C L, Leong T S
Unit of Rheumatology, Department of Medicine, Sarawak General Hospital, Sarawak, Malaysia,
Clin Rheumatol. 2015 Jan;34(1):175-8. doi: 10.1007/s10067-014-2671-6. Epub 2014 May 16.
We performed a cross-sectional study of all antiphospholipid syndrome (APS) patients during an 8-year period (2006-2013) to describe the clinical features, serology profiles, treatment regimes, and outcomes in our center. There were a total of 59 patients in our study with the female to male ratio of 9:1. They have a mean age of 41.6 ± 12.1 years and a mean duration of illness of 38.4 ± 68.5 months. The majority of patients presented with vascular thrombosis (69.5 %) with equal arterial and venous involvements. Twenty-six patients (44.1 %) presented with obstetric complications with recurrent abortions (32.2 %) as the main manifestation. Most patients were on daily warfarin doses of 2-6 mg (91.0 %) with target INR of 2-3. There was neither recurrent thrombosis nor bleeding complications documented. There were 80 % live births following treatment in our patients.
我们对2006年至2013年这8年间所有抗磷脂综合征（APS）患者进行了一项横断面研究，以描述我们中心患者的临床特征、血清学指标、治疗方案及治疗结果。我们的研究共有59例患者，男女比例为9:1。他们的平均年龄为41.6±12.1岁，平均病程为38.4±68.5个月。大多数患者表现为血管血栓形成（69.5%），动脉和静脉受累情况相同。26例患者（44.1%）出现产科并发症，主要表现为复发性流产（32.2%）。大多数患者每日服用华法林剂量为2 - 6mg（91.0%），目标国际标准化比值（INR）为2 - 3。未记录到复发性血栓形成或出血并发症。我们的患者治疗后活产率为80%。
